NA Lung Cancer Diagnostics Market - Industry Trends and Forecast to 2030
Description
NA Lung Cancer Diagnostics Market - Industry Trends and Forecast to 2030
The North America lung cancer diagnostics market is projected to register a substantial CAGR of 14.6% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030
Market Segmentation
North America Lung Cancer Diagnostics Market, By Product Type (Instruments, Consumables & Accessories), Test Type (Biomarkers Test, Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of the North America lung cancer diagnostics market are:
• Rise in prevalence and incidence of lung cancer
• Increase in healthcare expenditure for better health services
Market Players
Some of the major players operating in the North America lung cancer diagnostics market are:
• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• Abbott
• Quest Diagnostics Incorporated
• Biodesix
• Bio-Rad Laboratories, Inc.
• Biocartis
• Danaher
• DiaSorin S.p.A.
• Exact Sciences UK, Ltd. (a subsidiary of Exact Science Corporation)
• 20/20 Gene Systems
• Guardant Health, Inc.
• Inivata Ltd.
• Vela Diagnostics
• LalPathLabs.com
• LungLife AI, Inc.
• Myriad Genetics, Inc.
• NeoGenomics Laboratories
• NanoString
• Oncocyte Corporation
• PerkinElmer Inc.
• QIAGEN
• Siemens Healthcare GmbH
• Veracyte, Inc.
The North America lung cancer diagnostics market is projected to register a substantial CAGR of 14.6% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030
Market Segmentation
North America Lung Cancer Diagnostics Market, By Product Type (Instruments, Consumables & Accessories), Test Type (Biomarkers Test, Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of the North America lung cancer diagnostics market are:
• Rise in prevalence and incidence of lung cancer
• Increase in healthcare expenditure for better health services
Market Players
Some of the major players operating in the North America lung cancer diagnostics market are:
• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• Abbott
• Quest Diagnostics Incorporated
• Biodesix
• Bio-Rad Laboratories, Inc.
• Biocartis
• Danaher
• DiaSorin S.p.A.
• Exact Sciences UK, Ltd. (a subsidiary of Exact Science Corporation)
• 20/20 Gene Systems
• Guardant Health, Inc.
• Inivata Ltd.
• Vela Diagnostics
• LalPathLabs.com
• LungLife AI, Inc.
• Myriad Genetics, Inc.
• NeoGenomics Laboratories
• NanoString
• Oncocyte Corporation
• PerkinElmer Inc.
• QIAGEN
• Siemens Healthcare GmbH
• Veracyte, Inc.
Table of Contents
221 Pages
- 1 Introduction
- 1.1 Objectives Of The Study
- 1.2 Market Definition
- 1.3 Overview Of North America Lung Cancer Diagnostics Market
- 1.4 Limitations
- 1.5 Markets Covered
- 2 Market Segmentation
- 2.1 Markets Covered
- 2.2 Geographical Scope
- 2.3 Years Considered For The Study
- 2.4 Currency And Pricing
- 2.5 Dbmr Tripod Data Validation Model
- 2.6 Multivariate Modelling
- 2.7 Product Type Lifeline Curve
- 2.8 Primary Interviews With Key Opinion Leaders
- 2.9 Dbmr Market Position Grid
- 2.10 Market Testing Type Coverage Grid
- 2.11 Vendor Share Analysis
- 2.12 Secondary Sources
- 2.13 Assumptions
- 3 Executive Summary
- 4 Premium Insights
- 4.1 Porter’s Five Forces
- 4.2 Pestel Analysis
- 4.3 Industry Insights
- 5 Epidermiology
- 6 Regulations
- 7 Market Overview
- 7.1 Drivers
- 7.1.1 Unmet Need For Non-invasive, Accurate, And Reliable Diagnostic Tests For Earlier Cancer Detection
- 7.1.2 Increasing Early Diagnosis Of Lungs Cancer
- 7.1.3 Increasing Cases Of Lung Cancer
- 7.1.4 Rise In Product Approvals
- 7.2 Restraints
- 7.2.1 Poor & Late Diagnosis Of Lung Cancer
- 7.2.2 High False-positives And Poor Sensitivity
- 7.3 Opportunities
- 7.3.1 Rise In Healthcare Expenditure For Cancer Diagnosis And Treatment
- 7.3.2 Government Initiatives Toward Cancer Diagnostics
- 7.3.3 Rising Awareness Of Lung Cancer
- 7.4 Challenges
- 7.4.1 Stringent Regulatory Framework For The Approval And Commercialization Of Cancer Diagnostic Products
- 7.4.2 Increased Cost, Safety, And Convenience Issues
- 7.4.3 Lack Of Skilled And Certified Professionals
- 8 North America Lung Cancer Diagnostics Market, By Product Type
- 8.1 Overview
- 8.2 Instruments
- 8.2.1 Imaging Instruments
- 8.2.1.1 Ct Systems
- 8.2.1.2 Ultrasound Systems
- 8.2.1.3 Mri Systems
- 8.2.1.4 Others
- 8.2.2 Biopsy Instruments
- 8.2.2.1 Needle Biopsy
- 8.2.2.2 Endoscopic Biopsy
- 8.2.2.3 Core Biopsy
- 8.2.2.4 Others
- 8.2.3 Pathology-based Instruments
- 8.2.3.1 Slide Staining Systems
- 8.2.3.2 Tissue Processing Systems
- 8.2.3.3 Cell Processors
- 8.2.3.4 Pcr Instruments
- 8.2.3.5 Others Pathology-based Instruments
- 8.3 Consumables And Accessories
- 8.3.1 Kits
- 8.3.1.1 Dna Polymerase Kits
- 8.3.1.2 Nucleic Acid Isolation Kits
- 8.3.1.3 Pcr Kits
- 8.3.1.4 Others
- 8.3.2 Reagents
- 8.3.2.1 Assays
- 8.3.2.2 Buffers
- 8.3.2.3 Primers
- 8.3.2.4 Others
- 8.3.3 Probes
- 8.3.4 Other Consumables
- 9 North America Lung Cancer Diagnostics Market, By Test Type
- 9.1 Overview
- 9.2 Imaging Test
- 9.2.1 Computed Tomography (Ct) Scan
- 9.2.2 Positron Emission Tomography (Pet) Scan
- 9.2.3 Chest X-ray
- 9.2.4 Bone Scan
- 9.2.5 Mri
- 9.2.6 Others
- 9.3 Biomarkers Test
- 9.3.1 Egfr Mutation Test
- 9.3.2 Kras Mutation Test
- 9.3.3 Alk Test
- 9.3.4 Her2 Test
- 9.3.5 Others
- 9.4 Biopsy
- 9.4.1 Needle Biopsy
- 9.4.2 Bronchoscopy Biopsy
- 9.4.3 Core Biopsy
- 9.4.4 Others
- 9.5 Blood Test
- 9.5.1 Complete Blood Count (Cbc)
- 9.5.2 Blood Chemistry Tests
- 9.5.3 Others
- 9.6 Others
- 10 North America Lung Cancer Diagnostics Market, By Cancer Type
- 10.1 Overview
- 10.2 Non-small Cell Lung Cancer
- 10.3 Small Cell Lung Cancer
- 11 North America Lung Cancer Diagnostics Market, By End User
- 11.1 Overview
- 11.2 Hospital
- 11.3 Associated Labs
- 11.4 Independent Diagnostic Laboratories
- 11.5 Diagnostic Imaging Centers
- 11.6 Cancer Research Institutes
- 11.7 Others
- 12 North America Lung Cancer Diagnostics Market, By Distribution Channel
- 12.1 Overview
- 12.2 Direct Tender
- 12.3 Retail Sales
- 13 North America Lung Cancer Diagnostics Market, By Region
- 13.1 North America
- 13.1.1 U.S.
- 13.1.2 Canada
- 13.1.3 Mexico
- 14 North America Lung Cancer Diagnostics Market, Company Landscape
- 14.1 Company Share Analysis: North America
- 15 Swot Analysis
- 16 Company Profile
- 16.1 F. Hoffmann-la Roche Ltd. (2022)
- 16.1.1 Company Snapshot
- 16.1.2 Revenue Analysis
- 16.1.3 Company Share Analysis
- 16.1.4 Product Portfolio
- 16.1.5 Recent Developments
- 16.2 Thermo Fisher Scientific Inc. (2022)
- 16.2.1 Company Snapshot
- 16.2.2 Revenue Analysis
- 16.2.3 Company Share Analysis
- 16.2.4 Product Portfolio
- 16.2.5 Recent Developments
- 16.3 Abbott (2022)
- 16.3.1 Company Snapshot
- 16.3.2 Revenue Analysis
- 16.3.3 Company Share Analysis
- 16.3.4 Product Portfolio
- 16.3.5 Recent Developments
- 16.4 Quest Diagnostics Incorporated (2022)
- 16.4.1 Company Snapshot
- 16.4.2 Revenue Analysis
- 16.4.3 Company Share Analysis
- 16.4.4 Product Portfolio
- 16.4.5 Recent Developments
- 16.5 Biodesix (2022)
- 16.5.1 Company Profile
- 16.5.2 Revenue Analysis
- 16.5.3 Company Share Analysis
- 16.5.4 Product Portfolio
- 16.5.5 Recent Developments
- 16.6 Amoy Diagnostics Co., Ltd. (2022)
- 16.6.1 Company Snapshot
- 16.6.2 Product Portfolio
- 16.6.3 Recent Developments
- 16.7 Bio-rad Laboratories, Inc. (2022)
- 16.7.1 Company Snapshot
- 16.7.2 Revenue Analysis
- 16.7.3 Product Portfolio
- 16.7.4 Recent Developments
- 16.8 Biocartis (2022)
- 16.8.1 Company Snapshot
- 16.8.2 Revenue Analysis
- 16.8.3 Product Portfolio
- 16.8.4 Recent Developments
- 16.9 Boditech Med Inc.
- 16.9.1 Company Profile
- 16.9.2 Product Portfolio
- 16.9.3 Recent Developments
- 16.10 Danaher (2022)
- 16.10.1 Company Snapshot
- 16.10.2 Revenue Analysis
- 16.10.3 Product Portfolio
- 16.10.4 Recent Developments
- 16.11 Diasorin S.P.A. (2022)
- 16.11.1 Company Snapshot
- 16.11.2 Revenue Analysis
- 16.11.3 Product Portfolio
- 16.11.4 Recent Developments
- 16.12 Exact Sciences Uk, Ltd. (Subsidiary Of Exact Science Corporation) (2022)
- 16.12.1 Company Snapshot
- 16.12.2 Revenue Analysis
- 16.12.3 Product Portfolio
- 16.12.4 Recent Developments
- 16.13 20/20 Gene Systems
- 16.13.1 Company Profile
- 16.13.2 Product Portfolio
- 16.13.3 Recent Developments
- 16.14 Guardant Health Inc.
- 16.14.1 Company Profile
- 16.14.2 Product Portfolio
- 16.14.3 Recent Developments
- 16.15 Inivata Ltd.
- 16.15.1 Company Profile
- 16.15.2 Product Portfolio
- 16.15.3 Recent Developments
- 16.16 Lalpathlabs.Com (2022)
- 16.16.1 Company Snapshot
- 16.16.2 Revenue Analysis
- 16.16.3 Product Portfolio
- 16.16.4 Recent Developments
- 16.17 Lunglife Ai, Inc. (2022)
- 16.17.1 Company Snapshot
- 16.17.2 Product Portfolio
- 16.17.3 Recent Developments
- 16.18 Medgenome
- 16.18.1 Company Snapshot
- 16.18.2 Product Portfolio
- 16.18.3 Recent Developments
- 16.19 Myriad Genetics, Inc.
- 16.19.1 Company Snapshot
- 16.19.2 Product Portfolio
- 16.19.3 Recent Developments
- 16.20 Neogenomics Laboratories (2022)
- 16.20.1 Company Snapshot
- 16.20.2 Revenue Analysis
- 16.20.3 Product Portfolio
- 16.20.4 Recent Developments
- 16.21 Nanostring (2022)
- 16.21.1 Company Snapshot
- 16.21.2 Revenue Analysis
- 16.21.3 Product Portfolio
- 16.21.4 Recent Developments
- 16.22 Nanoentek
- 16.22.1 Company Profile
- 16.22.2 Product Portfolio
- 16.22.3 Recent Developments
- 16.23 Oncocyte Corporation
- 16.23.1 Company Profile
- 16.23.2 Service Portfolio
- 16.23.3 Recent Developments
- 16.24 Perkinelmer Inc
- 16.24.1 Company Profile
- 16.24.2 Revenue Analysis
- 16.24.3 Product Portfolio
- 16.24.4 Recent Developments
- 16.25 Plexbio
- 16.25.1 Company Snapshot
- 16.25.2 Product Portfolio
- 16.25.3 Recent Developments
- 16.26 Qiagen
- 16.26.1 Company Snapshot
- 16.26.2 Revenue Analysis
- 16.26.3 Product Portfolio
- 16.26.4 Recent Developments 210
- List Of Tables
- Table 1 Different Types Of Cancer Screening Tests For Different Types Of Cancers
- Table 2 Lung Cancer Rates
- Table 3 Approved Diagnostics Of Lungs Cancer
- Table 4 North America Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 5 North America Instruments In Lung Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million)
- Table 6 North America Imaging Instruments In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 7 North America Biopsy Instruments In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 8 North America Pathology-based Instruments In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 9 North America Consumables & Accessories In Lung Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million)
- Table 10 North America Consumables And Accessories In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 11 North America Kits In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 12 North America Reagents In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 13 North America Lung Cancer Diagnostics Market, By Test Type, 2021-2030 (Usd Million)
- Table 14 North America Imaging Test In Lung Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million)
- Table 15 North America Imaging Test In Lung Cancer Diagnostics Market, By Test Type, 2021-2030 (Usd Million)
- Table 16 North America Biomarkers Test In Lung Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million)
- Table 17 North America Biomarkers Test In Lung Cancer Diagnostics Market, By Test Type, 2021-2030 (Usd Million)
- Table 18 North America Biopsy In Lung Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million)
- Table 19 North America Biopsy In Lung Cancer Diagnostics Market, By Test Type, 2021-2030 (Usd Million)
- Table 20 North America Blood Test In Lung Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million)
- Table 21 North America Blood Test In Lung Cancer Diagnostics Market, By Test Type, 2021-2030 (Usd Million)
- Table 22 North America Others In Lung Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million)
- Table 23 North America Lung Cancer Diagnostics Market, By Cancer Type, 2021-2030 (Usd Million)
- Table 24 North America Non-small Cell Lung Cancer In Lung Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million)
- Table 25 North America Small Cell Lung Cancer In Lung Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million)
- Table 26 North America Lung Cancer Diagnostics Market, By End User, 2021-2030 (Usd Million)
- Table 27 North America Hospital In Lung Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million)
- Table 28 North America Associated Labs In Lung Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million)
- Table 29 North America Independent Diagnostic Laboratories In Lung Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million)
- Table 30 North America Diagnostic Imaging Centers In Lung Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million)
- Table 31 North America Cancer Research Institutes In Lung Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million)
- Table 32 North America Others In Lung Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million)
- Table 33 North America Lung Cancer Diagnostics Market, By Distribution Channel, 2021-2030 (Usd Million)
- Table 34 North America Direct Tender In Lung Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million)
- Table 35 North America Retail Sales In Lung Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million)
- Table 36 North America Lung Cancer Diagnostics Market, By Country, 2021-2030 (Usd Million)
- Table 37 North America Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 38 North America Instruments In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 39 North America Pathology-based Instruments In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 40 North America Imaging Instruments In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 41 North America Biopsy Instruments In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 42 North America Consumables And Accessories In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 43 North America Kits In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 44 North America Reagents In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 45 North America Lung Cancer Diagnostics Market, By Test Type, 2021-2030 (Usd Million)
- Table 46 North America Biomarkers Test In Lung Cancer Diagnostics Market, By Test Type, 2021-2030 (Usd Million)
- Table 47 North America Imaging Test In Lung Cancer Diagnostics Market, By Test Type, 2021-2030 (Usd Million)
- Table 48 North America Biopsy In Lung Cancer Diagnostics Market, By Test Type, 2021-2030 (Usd Million)
- Table 49 North America Blood Test In Lung Cancer Diagnostics Market, By Test Type, 2021-2030 (Usd Million)
- Table 50 North America Lung Cancer Diagnostics Market, By Cancer Type, 2021-2030 (Usd Million)
- Table 51 North America Lung Cancer Diagnostics Market, By End User, 2021-2030 (Usd Million)
- Table 52 North America Lung Cancer Diagnostics Market, By Distribution Channel, 2021-2030 (Usd Million)
- Table 53 U.S. Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 54 U.S. Instruments In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 55 U.S. Pathology-based Instruments In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 56 U.S. Imaging Instruments In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 57 U.S. Biopsy Instruments In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 58 U.S. Consumables And Accessories In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 59 U.S. Kits In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 60 U.S. Reagents In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 61 U.S. Lung Cancer Diagnostics Market, By Test Type, 2021-2030 (Usd Million)
- Table 62 U.S. Biomarkers Test In Lung Cancer Diagnostics Market, By Test Type, 2021-2030 (Usd Million)
- Table 63 U.S. Imaging Test In Lung Cancer Diagnostics Market, By Test Type, 2021-2030 (Usd Million)
- Table 64 U.S. Biopsy In Lung Cancer Diagnostics Market, By Test Type, 2021-2030 (Usd Million)
- Table 65 U.S. Blood Test In Lung Cancer Diagnostics Market, By Test Type, 2021-2030 (Usd Million)
- Table 66 U.S. Lung Cancer Diagnostics Market, By Cancer Type, 2021-2030 (Usd Million)
- Table 67 U.S. Lung Cancer Diagnostics Market, By End User, 2021-2030 (Usd Million)
- Table 68 U.S. Lung Cancer Diagnostics Market, By Distribution Channel, 2021-2030 (Usd Million)
- Table 69 Canada Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 70 Canada Instruments In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 71 Canada Pathology-based Instruments In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 72 Canada Imaging Instruments In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 73 Canada Biopsy Instruments In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 74 Canada Consumables And Accessories In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 75 Canada Kits In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 76 Canada Reagents In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 77 Canada Lung Cancer Diagnostics Market, By Test Type, 2021-2030 (Usd Million)
- Table 78 Canada Biomarkers Test In Lung Cancer Diagnostics Market, By Test Type, 2021-2030 (Usd Million)
- Table 79 Canada Imaging Test In Lung Cancer Diagnostics Market, By Test Type, 2021-2030 (Usd Million)
- Table 80 Canada Biopsy In Lung Cancer Diagnostics Market, By Test Type, 2021-2030 (Usd Million)
- Table 81 Canada Blood Test In Lung Cancer Diagnostics Market, By Test Type, 2021-2030 (Usd Million)
- Table 82 Canada Lung Cancer Diagnostics Market, By Cancer Type, 2021-2030 (Usd Million)
- Table 83 Canada Lung Cancer Diagnostics Market, By End User, 2021-2030 (Usd Million)
- Table 84 Canada Lung Cancer Diagnostics Market, By Distribution Channel, 2021-2030 (Usd Million)
- Table 85 Mexico Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 86 Mexico Instruments In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 87 Mexico Pathology-based Instruments In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 88 Mexico Imaging Instruments In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 89 Mexico Biopsy Instruments In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 90 Mexico Consumables And Accessories In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 91 Mexico Kits In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 92 Mexico Reagents In Lung Cancer Diagnostics Market, By Product Type, 2021-2030 (Usd Million)
- Table 93 Mexico Lung Cancer Diagnostics Market, By Test Type, 2021-2030 (Usd Million)
- Table 94 Mexico Biomarkers Test In Lung Cancer Diagnostics Market, By Test Type, 2021-2030 (Usd Million)
- Table 95 Mexico Imaging Test In Lung Cancer Diagnostics Market, By Test Type, 2021-2030 (Usd Million)
- Table 96 Mexico Biopsy In Lung Cancer Diagnostics Market, By Test Type, 2021-2030 (Usd Million)
- Table 97 Mexico Blood Test In Lung Cancer Diagnostics Market, By Test Type, 2021-2030 (Usd Million)
- Table 98 Mexico Lung Cancer Diagnostics Market, By Cancer Type, 2021-2030 (Usd Million)
- Table 99 Mexico Lung Cancer Diagnostics Market, By End User, 2021-2030 (Usd Million)
- Table 100 Mexico Lung Cancer Diagnostics Market, By Distribution Channel, 2021-2030 (Usd Million) 130
- List Of Figures
- Figure 1 North America Lung Cancer Diagnostics Market: Segmentation
- Figure 2 North America Lung Cancer Diagnostics Market: Data Triangulation
- Figure 3 North America Lungs Cancer Diagnostics Market: Droc Analysis
- Figure 4 North America Lung Cancer Diagnostics Market: North America Vs Regional Market Analysis
- Figure 5 North America Lung Cancer Diagnostic Market: Company Research Analysis
- Figure 6 North America Lung Cancer Diagnostics Market: Interview Demographics
- Figure 7 North America Lung Cancer Diagnostics Market: Dbmr Market Position Grid
- Figure 8 North America Lung Cancer Diagnostics Market: Market End User Coverage Grid
- Figure 9 North America Lung Cancer Diagnostics Market: Vendor Share Analysis
- Figure 10 North America Lung Cancer Diagnostics Market: Segmentation
- Figure 11 The Increase In The Awareness About Lung Cancer Is Expected To Drive The North America Lung Cancer Diagnostics Market In The Forecast Period
- Figure 12 Instruments Segment Is Expected To Account For The Largest Share Of The North America Lung Cancer Diagnostics Market In 2023 & 2030
- Figure 13 Drivers, Restraints, Opportunities, And Challenges Of The North America Lung Cancer Diagnostics Market
- Figure 14 The North America Mortality Rate Due To Cancer
- Figure 15 The Data Given Below Shows The Increasing North America Cancer Rate In 2020
- Figure 16 Barriers To Early Cancer Diagnosis And Treatment
- Figure 17 North America Lung Cancer Diagnostics Market: By Product Type, 2022
- Figure 18 North America Lung Cancer Diagnostics Market: By Product Type, 2023-2030 (Usd Million)
- Figure 19 North America Lung Cancer Diagnostics Market: By Product Type, Cagr (2023-2030)
- Figure 20 North America Lung Cancer Diagnostics Market: By Product Type, Lifeline Curve
- Figure 21 North America Lung Cancer Diagnostics Market: By Test Type, 2022
- Figure 22 North America Lung Cancer Diagnostics Market: By Test Type, 2023-2030 (Usd Million)
- Figure 23 North America Lung Cancer Diagnostics Market: By Test Type, Cagr (2023-2030)
- Figure 24 North America Lung Cancer Diagnostics Market: By Test Type, Lifeline Curve
- Figure 25 North America Lung Cancer Diagnostics Market: By Cancer Type, 2022
- Figure 26 North America Lung Cancer Diagnostics Market: By Cancer Type, 2023-2030 (Usd Million)
- Figure 27 North America Lung Cancer Diagnostics Market: By Cancer Type, Cagr (2023-2030)
- Figure 28 North America Lung Cancer Diagnostics Market: By Cancer Type, Lifeline Curve
- Figure 29 North America Lung Cancer Diagnostics Market: By End User, 2022
- Figure 30 North America Lung Cancer Diagnostics Market: By End User, 2023-2030 (Usd Million)
- Figure 31 North America Lung Cancer Diagnostics Market: By End User, Cagr (2023-2030)
- Figure 32 North America Lung Cancer Diagnostics Market: By End User, Lifeline Curve
- Figure 33 North America Lung Cancer Diagnostics Market: By Distribution Channel, 2022
- Figure 34 North America Lung Cancer Diagnostics Market: By Distribution Channel, 2023-2030 (Usd Million)
- Figure 35 North America Lung Cancer Diagnostics Market: By Distribution Channel, Cagr (2023-2030)
- Figure 36 North America Lung Cancer Diagnostics Market: By Distribution Channel, Lifeline Curve
- Figure 37 North America Lung Cancer Diagnostics Market: Snapshot (2022)
- Figure 38 North America Lung Cancer Diagnostics Market: By Country (2022)
- Figure 39 North America Lung Cancer Diagnostics Market: By Country (2023 & 2030)
- Figure 40 North America Lung Cancer Diagnostics Market: By Country (2022 & 2030)
- Figure 41 North America Lung Cancer Diagnostics Market: By Product Type (2023-2030)
- Figure 42 North America Lung Cancer Diagnostics Market: Company Share 2022 (%) 130
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.



